Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

19 Dec 2014
Price Change (% chg)

-0.25p (-0.19%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for VEC.L


Vectura Group plc (Vectura) is a developer of therapies principally for the treatment of respiratory diseases. The Company is engaged in developing treatments for respiratory diseases. Vectura’s products target diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The Company’s pharmaceutical business... (more)


Beta: -0.13
Market Cap (Mil.): £516.16
Shares Outstanding (Mil.): 402.46
Dividend: --
Yield (%): --


  VEC.L Industry Sector
P/E (TTM): -- 37.39 38.03
EPS (TTM): -0.02 -- --
ROI: -3.35 19.00 18.26
ROE: -3.65 19.79 19.16
Search Stocks

BRIEF-Vectura's asthma drug meets main goal in mid-stage trial

* Investigational drug/device combination VR475 met primary endpoint and has shown significant clinical benefit in a phase IIb/III trial in severe asthma patients

11 Dec 2014

BRIEF-Vectura gets marketing nod for Airflusal Forspiro in Ireland and Czech Republic

* Approval in Ireland and Czech Republic for innovative respiratory inhaler airflusal forspiro

19 Nov 2014

BRIEF-Vectura names Andrew Oakley as CFO

* Oakley will succeed Paul Oliver as CFO, executive director, and company secretary effective from 1 January 2015 Source text for Eikon: Further company coverage:

18 Nov 2014

BRIEF-Vectura H1 rev up 14 pct

* Nva237 is expected to be filed in us by novartis in q4 2014 Source text for Eikon: Further company coverage:

18 Nov 2014

BRIEF-Vectura says partner Novartis signs marketing deal with Pfizer UK

* Announcement of commercial arrangement with Pfizer UK to promote Ultibro Breezhaler and Seebri Breezhaler in United Kingdom Source text for Eikon: Further company coverage:

04 Sep 2014

BRIEF-Vectura performance from April to date in line with board's expectations

* Product pipeline is progressing in line with board's expectations

19 Aug 2014

BRIEF-Vectura says in US collaboration agreement for VR506 asthma therapy

* Announces a further US collaboration agreement with a leading international pharmaceutical company for VR506 asthma therapy

30 Jun 2014

Earnings vs. Estimates

Search Stocks